| Size | Price | |
|---|---|---|
| 500mg | ||
| 1g | ||
| Other Sizes |
| Targets |
HSP90
|
|---|---|
| ln Vivo |
Cemdomespib (KU-596; 2, 10, or 20 mg/kg; ip; given once weekly for 6 weeks) dose-dependently corrects the pre-existing psychosensory abnormalities after 8 weeks of diabetes. Moreover, cemdomespib dose-dependently reverses the impairments in motor (MNCV) and sensory (SNCV) nerve conduction velocities brought on by diabetes[1]. The sensory hypoalgesia in WT mice is markedly reversed by cemdomespib (20 mg/kg; oral gavage once per week for 4 weeks), but not in Hsp70 KO mice[1].
|
| Animal Protocol |
Animal/Disease Models: Diabetic Swiss Webster mice [1]
Doses: 2, 10, or 20 mg/kg Route of Administration: Administered after 8 weeks of diabetes via once per week intra-peritoneal injections. Experimental Results: Improved diabetes induced hypoalgesia and sensory neuron bioenergetic deficits in a dose-dependent manner. |
| References |
|
| Molecular Formula |
C24H30FNO6
|
|---|---|
| Molecular Weight |
447.50
|
| Exact Mass |
447.205
|
| CAS # |
1450642-92-8
|
| PubChem CID |
60148493
|
| Appearance |
Typically exists as solid at room temperature
|
| LogP |
2.3
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
7
|
| Rotatable Bond Count |
7
|
| Heavy Atom Count |
32
|
| Complexity |
619
|
| Defined Atom Stereocenter Count |
4
|
| SMILES |
CC(=O)NCCC1=C(C=C(C=C1)O[C@H]2[C@@H]([C@@H]([C@H](C(O2)(C)C)OC)O)O)C3=CC(=CC=C3)F
|
| InChi Key |
PDBWOHBMJQOBHL-WBADGQHESA-N
|
| InChi Code |
InChI=1S/C24H30FNO6/c1-14(27)26-11-10-15-8-9-18(13-19(15)16-6-5-7-17(25)12-16)31-23-21(29)20(28)22(30-4)24(2,3)32-23/h5-9,12-13,20-23,28-29H,10-11H2,1-4H3,(H,26,27)/t20-,21+,22+,23+/m0/s1
|
| Chemical Name |
N-[2-[4-[(2R,3R,4S,5R)-3,4-dihydroxy-5-methoxy-6,6-dimethyloxan-2-yl]oxy-2-(3-fluorophenyl)phenyl]ethyl]acetamide
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: Cemdomespib (KU-596) is prepared in 0.1 M Captisol (β-cyclodextrin sulfobutylethers) [1]. (Please use freshly prepared in vivo formulations for optimal results.)
|
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.2346 mL | 11.1732 mL | 22.3464 mL | |
| 5 mM | 0.4469 mL | 2.2346 mL | 4.4693 mL | |
| 10 mM | 0.2235 mL | 1.1173 mL | 2.2346 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
